Microbial production of novel sulphated alkaloids for drug discovery

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Matsumura, Eitaro ^a   Nakagawa, Akira ^a   Tomabechi, Yusuke ^b   Ikushiro, Shinichi ^c   Sakaki, Toshiyuki ^c   Katayama, Takane ^d   Yamamoto, Kenji ^a   Kumagai, Hidehiko ^a   Sato, Fumihiko ^d   Minami, Hiromichi ^a  

^a ISHIKAWA PREFECTURAL UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; BENZYLISOQUINOLINE DERIVATIVE; RETICULINE; SULFATE; TYROSINE 3 MONOOXYGENASE;

ANIMAL; BIOSYNTHESIS; DROSOPHILA MELANOGASTER; DRUG DEVELOPMENT; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; METABOLIC ENGINEERING; METABOLISM; PROCEDURES; TRANSGENIC ORGANISM;

ALKALOIDS; ANIMALS; BENZYLISOQUINOLINES; DROSOPHILA MELANOGASTER; DRUG DISCOVERY; ESCHERICHIA COLI; METABOLIC ENGINEERING; ORGANISMS, GENETICALLY MODIFIED; SULFATES; TYROSINE 3-MONOOXYGENASE;

EID: 85047632885     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-26306-7     Document Type: Article

References (31)

1. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311-335 (2012).
2. Song, M. C. et al. Microbial biosynthesis of medicinally important plant secondary metabolites. Nat. Prod. Rep. 31, 1497-1509 (2014).
3. Peplow, M. Synthetic biology's first malaria drug meets market resistance. Nature 530, 389-390 (2016).
4. Qian, P. & Yang, X.-W. Five new alkaloids from Coptidis Rhizoma-Euodiae Fructus couple and their cytotoxic activities against gastrointestinal cancer cells. Fitoterapia 93, 74-80 (2014).
5. Lv, J.-J. et al. Cytotoxic bisbenzylisoquinoline alkaloids from Stephania epigaea. J. Nat. Prod. 76, 926-932 (2013).
6. Ziegler, J. & Facchini, P. J. Alkaloid biosynthesis: metabolism and trafficking. Annu. Rev. Plant Biol. 59, 735-769 (2008).
7. Nakagawa, A. et al. A bacterial platform for fermentative production of plant alkaloids. Nat. Commun. 2, 326 (2011).
8. DeLoache, W. C. et al. An enzyme-coupled biosensor enables (S)-reticuline production in yeast from glucose. Nat. Chem. Biol. 11, 465-471 (2015).
9. Trenchard, I. J., Siddiqui, M. S., Thodey, K. & Smolke, C. D. De novo production of the key branch point benzylisoquinoline alkaloid reticuline in yeast. Metab. Eng. 31, 74-83 (2015).
10. Nakagawa, A. et al. Total biosynthesis of opiates by stepwise fermentation using engineered Escherichia coli. Nat. Commun. 7, 10390 (2016).
11. Galanie, S., Thodey, K., Trenchard, I. J., Filsinger Interrante, M. & Smolke, C. D. Complete biosynthesis of opioids in yeast. Science 349, 1095-1100 (2015).
12. Berg, E. L. et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J. Pharmacol. Toxicol. Methods 61, 3-15 (2010).
13. Berg, E. L., Hsu, Y.-C. & Lee, J. A. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery. Adv. Drug Deliv. Rev. 69-70, 190-204 (2014).
14. Hernández-Romero, D., Sanchez-Amat, A. & Solano, F. A tyrosinase with an abnormally high tyrosine hydroxylase/dopa oxidase ratio. FEBS J. 273, 257-270 (2006).
15. Pribat, A. et al. FolX and FolM are essential for tetrahydromonapterin synthesis in Escherichia coli and Pseudomonas aeruginosa. J. Bacteriol. 192, 475-482 (2010).
16. Yamamoto, K. et al. Genetic engineering of Escherichia coli for production of tetrahydrobiopterin. Metab. Eng. 5, 246-254 (2003).
17. Wang, L.-Q. & James, M. O. Inhibition of sulfotransferases by xenobiotics. Curr. Drug Metab. 7, 83-104 (2006).
18. Berg, E. L., Yang, J. & Polokoff, M. A. Building predictive models for mechanism-of-action classification from phenotypic assay data sets. J. Biomol. Screen. 18, 1260-1269 (2013).
19. Martin, M. L. et al. Antispasmodic activity of benzylisoquinoline alkaloids analogous to papaverine. Planta Med. 59, 63-67 (1993).
20. Akiyama, H. et al. Expression of intercellular adhesion molecule (ICAM)1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol. 85, 628-634 (1993).
21. Hu, J., V den Steen, P. E., Sang, Q.-X. A. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498 (2007).
22. Rubio-Perez, J. M. & Morillas-Ruiz, J. M. A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci. World J. 2012, 756357 (2012).
23. Satoh, Y., Tajima, K., Munekata, M., Keasling, J. D. & Lee, T. S. Engineering of l-tyrosine oxidation in Escherichia coli and microbial production of hydroxytyrosol. Metab. Eng. 14, 603-610 (2012).
24. Sakakibara, Y. et al. Manganese-dependent Dopa/tyrosine sulfation in HepG2 human hepatoma cells: novel Dopa/tyrosine sulfotransferase activities associated with the human monoamine-form phenol sulfotransferase. Biochim. Biophys. Acta 1355, 102-106 (2003).
25. Dajani, R., Hood, A. M. & Coughtrie, M. W. H. A single amino acid, Glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Mol. Pharmacol. 54, 942-948 (1998).
26. Cook, I., Wang, T. & Leyh, T. S. Tetrahydrobiopterin regulates monoamine neurotransmitter sulfonation. Proc. Natl. Acad. Sci. USA 114, E5317-E5324 (2017).
27. Fossati, E. et al. Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid dihydrosanguinarine in Saccharomyces cerevisiae. Nat. Commun. 5, 3283 (2014).
28. Hori, K., Okano, S. & Sato, F. Efficient microbial production of stylopine using a Pichia pastoris expression system. Sci. Rep. 6, 22201 (2016).
29. Trenchard, I. J. & Smolke, C. D. Engineering strategies for the fermentative production of plant alkaloids in yeast. Metab. Eng. 30, 96-104 (2015).
30. Kim, J.-S. et al. Improvement of reticuline productivity from dopamine by using engineered Escherichia coli. Biosci. Biotechnol. Biochem. 77, 2166-2168 (2013).
31. Haselmayer, P. et al. Characterization of novel PI3K inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies. Front. Immunol. 5, 233 (2014).